Clinical Trial Update: Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 safety study of CC312 in adults with relapsed/refractory CD19-positive B-cell hematologic malignancies, and the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• CC312 (CC312)

Snippet

Sponsor: CytoCares Inc | Conditions: Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia | Phase 1 | Status: RECRUITING